ID27069A - Sediaan farmasi untuk pemilihan suplemen defisiensi estrogen dalam sistem pusat syaraf - Google Patents

Sediaan farmasi untuk pemilihan suplemen defisiensi estrogen dalam sistem pusat syaraf

Info

Publication number
ID27069A
ID27069A IDW20001592A ID20001592A ID27069A ID 27069 A ID27069 A ID 27069A ID W20001592 A IDW20001592 A ID W20001592A ID 20001592 A ID20001592 A ID 20001592A ID 27069 A ID27069 A ID 27069A
Authority
ID
Indonesia
Prior art keywords
transcription
central nervous
estradiol
oestrogen
nervous system
Prior art date
Application number
IDW20001592A
Other languages
English (en)
Inventor
Vladimir Patchev
Michael Oettel
Ina Thieme
Sigfrid Schwarz
Wolfgang Romer
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/de
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of ID27069A publication Critical patent/ID27069A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
IDW20001592A 1998-02-20 1999-02-10 Sediaan farmasi untuk pemilihan suplemen defisiensi estrogen dalam sistem pusat syaraf ID27069A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE1998121831 DE19821831A1 (de) 1998-05-15 1998-05-15 Pharmazeutische Präparate zur gezielten Substitution des Estrogenmangels im Zentralnervensystem

Publications (1)

Publication Number Publication Date
ID27069A true ID27069A (id) 2001-02-22

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001592A ID27069A (id) 1998-02-20 1999-02-10 Sediaan farmasi untuk pemilihan suplemen defisiensi estrogen dalam sistem pusat syaraf

Country Status (24)

Country Link
EP (1) EP1056460B1 (id)
JP (1) JP2002503694A (id)
KR (1) KR20010041107A (id)
CN (1) CN1291102A (id)
AT (1) ATE252388T1 (id)
AU (1) AU739071C (id)
BG (1) BG104689A (id)
BR (1) BR9909205A (id)
CA (1) CA2321498A1 (id)
CZ (1) CZ291764B6 (id)
DE (1) DE59907446D1 (id)
EA (1) EA002707B1 (id)
EE (1) EE03906B1 (id)
HU (1) HUP0100742A3 (id)
ID (1) ID27069A (id)
IL (1) IL137727A0 (id)
IS (1) IS5571A (id)
NO (1) NO20004153L (id)
NZ (1) NZ506049A (id)
PL (1) PL342313A1 (id)
SK (1) SK12152000A3 (id)
TR (1) TR200002400T2 (id)
UA (1) UA57830C2 (id)
WO (1) WO1999042108A1 (id)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253318T3 (es) * 2001-11-07 2006-06-01 Schering Ag Cribado in vitro de ligandos del receptor de estrogeno.
CN112189624A (zh) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) 一种利用受体基因沉默技术构建和鉴定女性ad模型的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19524937A1 (de) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann
WO1997003661A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Also Published As

Publication number Publication date
PL342313A1 (en) 2001-06-04
EP1056460B1 (de) 2003-10-22
CN1291102A (zh) 2001-04-11
EE200000477A (et) 2001-12-17
KR20010041107A (ko) 2001-05-15
AU2920999A (en) 1999-09-06
NZ506049A (en) 2002-09-27
CZ291764B6 (cs) 2003-05-14
JP2002503694A (ja) 2002-02-05
DE59907446D1 (de) 2003-11-27
BG104689A (en) 2001-04-30
EA002707B1 (ru) 2002-08-29
CZ20002938A3 (cs) 2001-01-17
WO1999042108A1 (de) 1999-08-26
TR200002400T2 (tr) 2000-11-21
EP1056460A1 (de) 2000-12-06
CA2321498A1 (en) 1999-08-26
ATE252388T1 (de) 2003-11-15
NO20004153L (no) 2000-10-09
HUP0100742A3 (en) 2002-07-29
UA57830C2 (uk) 2003-07-15
IL137727A0 (en) 2001-10-31
EA200000858A1 (ru) 2001-04-23
IS5571A (is) 2000-07-24
SK12152000A3 (sk) 2001-02-12
BR9909205A (pt) 2000-11-14
EE03906B1 (et) 2002-12-16
NO20004153D0 (no) 2000-08-18
HUP0100742A2 (hu) 2001-09-28
AU739071C (en) 2002-04-11
AU739071B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO1998027929A3 (de) Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder
WO1996019568A3 (en) Stabilized ribozyme analogs
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
TR199800648A1 (xx) �ki veya daha fazla etken madde i�in ila� verme sistemi.
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
AU2561195A (en) Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
MY137435A (en) Retinoid compounds (i)
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ID27069A (id) Sediaan farmasi untuk pemilihan suplemen defisiensi estrogen dalam sistem pusat syaraf
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
WO2001085165A3 (de) Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems
GR3025872T3 (en) Orally active derivatives of 1,3,5(10)-estratriene
ATE286739T1 (de) Verwendung einer pollenextrakt-haltigen verbindung zur behandlung erkrankungsbedingter gewichtszunahme
BR0113618A (pt) 17-metilenoesteróides, processos para a sua preparação e composições farmacêuticas contendo estes compostos
AU8624198A (en) 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments.
Cadman Roche brings new formulation of saquinavir to FDA. Food and Drug Administration
Romanenkova Regional demographic policy: goals, principles, possible solutions
Diamond Physician notes hazards of DES use to prevent pregnancy
Beraldo et al. Peculiarities of the oxytocic action of rat kallikrein
三木保 et al. Neuro-Endoscopic Antomy of The Posterior Fossa
MX9600140A (es) Uso de derivados de tocoferilo de vitamina e en composiciones oftalmicas.